Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02398240
Title Brentuximab for Newly Diagnosed Hodgkin Disease
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Mitchell Cairo
Indications

Hodgkin's lymphoma

Therapies

Brentuximab vedotin + Doxorubicin + Rituximab + Vincristine Sulfate

Brentuximab vedotin + Doxorubicin + Vincristine Sulfate

Age Groups: child | adult
Covered Countries USA

Facility Status City State Zip Country Details
New York Medical College Recruiting Valhalla New York 10595 United States Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field